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For a large num ber of women who are di ag nosed with breast can cer ev ery year, the avail able
treat ment op tions are ef fec tive, though phys i cally and men tally tax ing.  This work is a start -
ing point of a study of the ef  fi  cacy of bo  ron neu  tron cap  ture ther  apy as an al  ter  na  tive treat  -
ment for HER-2+ breast tu  mors. Us  ing HER-2-spe  cific monoclonal an  ti  bod  ies cou  pled
with a bo  ron-rich oligomeric phos  phate diester, it may be pos  si  ble to de  liver suf  fi  cient
amounts of 10B to a tu  mor of the breast to al low for se  lec  tive cell de  struc  tion via ir  ra  di  a  tion
by ther  mal neu  trons.  A com  pre  hen  sive com  pu  ta  tional model (MCNP) for ther  mal neu  -
tron ir  ra  di  a  tion of the breast is de  scribed, as well as the re  sults of cal  cu  la  tions made us  ing
this model, in or  der to de  ter  mine the op  ti  mum bo  ron con  cen  tra  tion within the tu  mor for
an ef  fec  tive bo  ron neu  tron cap  ture ther  apy treat  ment, as com  pared with tra  di  tional X-ray
ra dio ther apy.    The  re sults  in di cate  that  a  bo ron  con cen tra tion  of  50-60  mg per gram of tu  -
mor tis  sue is op  ti  mal when con  sid  er  ing treat  ment times, dose dis  tri  bu  tions and skin spar  -
ing.  How  ever, these re  sults are based upon best-guess as  sump  tions that must be ex  per  i  -
men tally  ver i fied.
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IN TRO DUC TION
Ac  cord  ing to the U. S. Na  tional Can  cer In  sti  -
tute, one of ev  ery eight women in the United States
will de  velop breast can  cer at some point dur  ing her
life  time.  For the ma  jor  ity of those who are for  tu  -
nate enough to be di  ag  nosed at an early stage of the
dis  ease, the most com  mon treat  ment op  tion is a
lumpectomy or mas  tec  tomy in which a por  tion or
the en  tire breast is re  moved.  The sur  gery is gen  er  -
ally fol lowed by che mo ther apy and/or ra dio ther apy 
to en sure to tal erad i ca tion of the ma lig nant cells [1].  
Though this is con  sid  ered rou  tine treat  ment with a
high suc  cess rate, the phys i  cal and men tal stress suf -
fered by the pa  tient can be ex  treme.  More  over, ap  -
prox i mately 30% of these tu mors are re sis tant to the 
nor mal av e nues of treat ment, due to an over-ex pres -
sion of the gene re  lated to the HER-2 (hu  man epi  -
der mal  growth  fac tor  re cep tor)  pro tein  which
pro motes  ma lig nant  cell  pro lif er a tion.    The  treat -
ment of these HER-2-pos  i  tive can  cers is ex  tremely
dif fi cult and re cur rence is prob a ble.  For this rea son, 
bo  ron neu  tron cap  ture ther  apy (BNCT) may pro  -
vide an ad  van  tage over tra  di  tional ther  apy in the
treat  ment of these types of can  cers.
Bo ron neu tron cap ture ther apy is a bi nary can -
cer treat  ment de  signed to de  liver a le  thal dose to
ma  lig  nant cells while spar  ing the sur  round  ing
healthy tis  sue.  Pro  posed in 1936, BNCT has been
the  topic  of  on go ing  clin i cal  in ves ti ga tion  for  the
treat  ment of ad  vanced glioma and mel  a  noma since
the early 1950’s [2].  The  the o ret i cal  con cept  of
BNCT (il  lus  trated in fig. 1) is to se  lec  tively de  liver
10B to tu  mor cells, which are then ir  ra  di  ated with a
beam of ther  mal (or epi  ther  mal) neu  trons.  The re  -
sult ing re ac tion (eq. 1) re leases an al pha par ti cle and 
a lith ium ion, both mas  sively charged par  ti  cles with
high lin  ear en  ergy trans  fer (LET)
10 1 11 7 4 2 79 B n B Li He MeV + ® ® + + [ ] . (1)
Of the 2.79 MeV re  leased in the re  ac  tion,
1.47 MeV and 0.84 MeV are im  parted to the al  -
pha and the lith  ium ion, re  spec  tively, in the form
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these par ti cles, this en ergy is de pos ited over a very
short range of only 10 to 15 mm com  bined (the
ap prox i mate  di am e ter  of  a  hu man  cell).  This
short range en  sures that all en  ergy re  leased in the
re  ac  tion is de  pos  ited within the cell in which the
re  ac  tion takes place.  On a larger scale, pro  vided
that the ad min is tered  10B is con fined to the tu mor 
vol ume,  the  ma jor ity  of  ra di a tion-in duced  dam -
age will oc  cur within the tu  mor. The dose to the
sur  round  ing healthy tis  sue (due to ther  mal neu  -
trons and a 0.48 MeV gamma that is emit  ted in
94% of the 10B(n,a)7Li  re ac tions  [2]) is greatly
re duced  in  com par i son  to  tra di tional  X-ray  ra dio -
ther  apy. How  ever, the ef  fec  tive  ness of this treat  -
ment is lim  ited by the abil  ity to se  lec  tively de  liver
bo  ron to the tu  mor cells. For the treat  ment of
glioma, it has been shown that a con  cen  tra  tion of
ap prox i mately  10-30  mg of 10B per gram is re  -
quired within the tu  mor, with a tu  mor to nor  mal
tis  sue con  cen  tra  tion ra  tio of at least five to one
[4].  It may be pos si ble to achieve these con di tions 
for the ap  pli  ca  tion of BNCT in the treat  ment of
breast  can cer  us ing  monoclonal  an ti bod ies
(MABs) and oligomeric phos  phate diesters
(OPDs).
It is known that ap prox i mately 30% of all breast
can  cers ex  hibit an over-ex  pres  sion of the HER-2 gene
[5].  These  HER-2-pos i tive  tu mors  are  sta tis ti cally
most re  sil  ient to treat  ment, due to the fact that am  pli  -
fi  ca  tion of the HER-2 gene causes in  creased num  bers
of HER-2 re  cep  tor sites at the cell sur  face which, in
turn, cause in  creased pro  lif  er  a  tion of the tu  mor cells. 
How  ever, it has been shown that treat  ing
HER-2-pos i tive breast can cers with MAB (sub stances 
that bind to and there  fore block spe  cific re  cep  tors at
the cell sur face) causes a re duc tion in this un con trolled 
growth [6].  The MAB spe  cific to HER-2 re  cep  tor
sites is known as Trastuzumab (avail  able un  der the
brand name Herceptin®) and is cur  rently be  ing used
as a treat  ment op  tion for in  creas  ing the sur  vival time
of pa  tients with HER-2-pos  i  tive breast can  cer.  If
com  bined with OPDs  which are eas  ily imprenated
with 10B and eas  ily linked to MABs, Trastuzumab
may be  come an ef  fec  tive bo  ron de  liv  ery agent for the
treat  ment of breast can  cer us ing BNCT.  Un  like tra  di -
tional bo  ron de  liv  ery agents used for the treat  ment of
glioma with BNCT, OPDs have been shown to ex  -
hibit highly se  lec  tive up  take within the nu  cleus of a
cell [7].  The pro posed mech a nism of ac tion is that the
com  bined MAB-OPD mol  e  cule binds to the HER-2
re  cep  tor sites at the sur  face of the tu  mor cells, where
the bo  ron-rich OPD is then taken up by the cell and
ac  cu  mu  lated in the nu  cleus.  When ex  posed to a ther  -
mal neu  tron beam, neu  trons are ab  sorbed by the 10B
and high en  ergy, high-LET ra  di  a  tion is emit  ted.  The
re  sult is ir  rep  a  ra  ble dam  age to the cell DNA, even  tu  -
ally lead  ing to apoptosis.
The fo cus of this work is the de vel op ment of
a com  pu  ta  tional model with which to study ther  -
mal neu  tron ir  ra  di  a  tion of the breast, as this is a
novel ap pli ca tion of BNCT.  The pri mary pa ram e -
ters of in ter est in this study are the ab sorbed doses 
in both the tu  mor and the sur  round  ing healthy
tis  sue, as well as the con  cen  tra  tion of bo  ron
within the tu  mor re  quired to achieve the desired
therapeutic results.
METH ODS
Com pu ta tional  model
For the pur  pose of de  ter  min  ing to  tal dose
rates due to ther  mal neu  tron ir  ra  di  a  tion of the
breast, a com  plex com  pu  ta  tional model was de  vel  -
oped us  ing the Monte Carlo N-Par  ti  cle (MCNP)
trans  port code, ver  sion 5, de vel  oped at Los Alamos
Na tional  Lab o ra tory  [8].  The model is based on a
com pu ta tional  mammogram  sim u la tion  de vel oped
by Baki} et al. [9],  with  slight  sim pli fi ca tions  made
for ease of mod  el  ing and run-time re  duc  tions.  The
ge  om  e  try, shown in fig. 2, con  sists of three re  gions:
ad  i  pose tis  sue (AT), fibroglandular tis  sue (FGT),
and ma  lig  nant tu  mor tis  sue.  As with a nor  mal hu  -
man fe  male breast, the model is com  posed pri  mar  -
ily of AT, with an FGT re  gion ex  tend  ing para  boli  -
cally in  ward from the area di  rectly be  hind the
nip  ple.  The den  si  ties of AT and FGT are given as
0.93 g/cm3 and 1.04 g/cm3,  re spec tively  [10], and
the den sity of the tu mor tis sue is as sumed to be 10% 
greater than that of the FGT (this as  sump  tion is
likely low, and is there  fore con  ser  va  tive for this
study).  The tu  mor was mod  eled as a se  ries of cy  lin  -
dri cal  vol umes  (for  com pu ta tional  ease)  cen tered
be hind the nip ple.  The di men sions of the model are 
in di cated in fig. 2, and the el e men tal com po si tion of 
each tis  sue type given in tab. 1.
 28 Nu clear  Tech nol ogy  &  Ra di a tion  Pro tec tion  –1/2005
Fig  ure 1. BNCT cell kill  ing mech  a  nismPar  al  lel op  posed neu  tron beams were mod  eled
as  mono-en er getic  pla nar  sources  po si tioned  as
shown in fig. 2.  The en  ergy of the source neu  trons
was set at 0.0253 eV (purely ther mal) and the di am e -
ter made equal to that of the tu mor vol ume.  The flux
of each beam was set to 5 ×109 cm-2s-1, which is an
ap prox i ma tion  of  the  max i mum  to tal  neu tron  flux
cur  rently avail  able for BNCT treat  ments [12]. It
should be noted that the ma  jor  ity of BNCT treat  -
ment  fa cil i ties  uti lize  epi ther mal  neu tron  beams,  as
they have been de  signed to treat brain tu  mors, for
which the neu  trons must pen  e  trate the skull be  fore
reach  ing the tu  mor and there  fore re  quire a higher
ini  tial en  ergy.  The cur  rent study ex  am  ines the ap  pli  -
ca  tion of purely ther  mal neu  trons, as pen  e  tra  tion of
dense struc  tures such as the skull is not re  quired for
the ir  ra  di  a  tion of breast tu  mors.  Fur  ther stud  ies will
uti lize epi ther mal spec tra to de ter mine whether these 
fa cil i ties of fer an ad van tage in spar ing healthy tis sue.
Radiobiology
If the re  sults of this ex  per  i  ment are to be com  -
pared with those of tra  di  tional X-ray ra  dio  ther  apy,
con sid er ations  must  be  made  for  the  rel a tive  bi o log i -
cal ef  fec  tive  ness of the high-LET par  ti  cles used in
BNCT (neu  trons, alphas, and heavy ions).  In pre  vi  -
ous BNCT ex  per  i  ments, each dose com  po  nent has
been  mul ti plied  by  a  bi o log i cal  ef fec tive ness  fac tor
which  is  de ter mined  ex per i men tally  for  each  par ti cle
and tu mor type, as well as the bo ron de liv ery agent [3].  
These fac  tors are known as the rel  a  tive bi  o  log  i  cal ef  -
fec  tive  ness (RBE) value for neu  trons and the com  -
pound  bi o log i cal  ef fec tive ness  (CBE)  value  for  prod -
ucts of the 10B(n,a)7Li re  ac  tion, and are de  scribed in
units of Gray-Equiv  a  lent (Gy-Eq).  They are de  ter  -
mined by the dose of high-LET ra  di  a  tion re  quired to
pro duce  a  bi o log i cal  ef fect  iden ti cal  to  a  known  X-ray
(usu  ally 250 kV at peak) dose. Be  cause ex  per  i  ments
us  ing the pro  posed Trastuzumab-OPD com  pound
have not yet taken place, av  er  age val  ues of 2.7 and 3.8
[3] were used for the pur poses of this model.  It should 
be noted, how ever, that the RBE and CBE val ues are a 
func  tion of bo  ron dis  tri  bu  tion within the cell; i. e.
higher if bo  ron is lo  cal  ized in the cy  to  plasm rather
than at the sur  face of the cell [3].  Since OPDs are
known to lo  cal  ize within the nu cleus  of each cell [7],
these pa ram e ters will likely have ex per i men tally-de ter -
mined val  ues that are much greater than the as  sumed
ones.  This as  sump  tion is there  fore con  ser  va  tive for
the pur  poses of this study.
RE SULTS
This model was used to ex  am  ine ther  mal neu  -
tron ir  ra  di  a  tion of the breast with vary  ing con  cen  -
tra tions of bo ron-10 in the tu mor vol ume. Data ob -
tained with  out the pres  ence of bo  ron pro  vides the
back  ground dose rate due to ther mal neu tron in  ter  -
ac  tions with the tis  sue.  It has been shown that the
min i mum con cen tra tion of bo ron within the tu mor 
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Fig ure 2. MCNP com pu ta tional breast model. Shown here: a wire di a gram of the model (a), cross-sec tional view in
the xz plane (b), and cross-sec  tional view in the xy plane (c). In each fig  ure, each dif  fer  ent ma  te  rial is in  di  cated by a
num  ber (1 – AT; 2 – FGT; 3 – tu  mor tis  sue) and the lo  ca  tion of the nip  ple is in  di  cated by N
Ta ble  1.  Chem i cal  com po si tions  of  tis sue  materials
Tissue
type
Chemical composition [wt%]
H C N O P
AT [10]
FGT [10]
Tumor [10, 11]
11.2
10.2
9.9
61.9
18.4
26.9
1.7
3.2
4.5
25.1
67.7
56.9
1.0
5.0
1.8re quired for ther a peu tic gain in BNCT glioma treat -
ments  is  ap prox i mately  30  mg  10B per gram of tu  -
mor tis  sue [4];  there fore,  bo ron  con cen tra tions
rang ing from 10 to 100 mg/g were stud ied.  The ob -
jec  tive of these cal  cu  la  tions is to de  ter  mine an es  ti  -
mate of the bo ron con  cen  tra  tion re  quired to de  liver
a le  thal dose to the en  tire tu  mor with  out ex  ceed  ing
the tol  er  ance thresh  old of the skin.
For  tra di tional  X-ray  ra dio ther apy  treat ment
of breast tu  mors, the av  er  age dose pre  scrip  tion is
ap prox i mately  50  Gy  [13] and the tol  er  ance limit of
hu  man skin for a sin  gle dose has been shown to be
18 Gy, at which point moist des  qua  ma  tion (peel  -
ing) oc  curs [3]. The ob  jec  tive of this study, thus, is
to  de ter mine  the  bo ron  con cen tra tion  re quired  to
de  liver 50 Gy-Eq to the tu  mor, while keep  ing the
dose to the skin be  low 18 Gy-Eq.  This was ac  com  -
plished by de ter  min  ing the dose rate in both the tu  -
mor and the sur round ing healthy tis sue due to ther -
mal neu  trons alone, first. The tu  mor was then
loaded  with  var i ous  con cen tra tions  of  bo ron  and
the ac  com  pa  ny  ing in  crease in dose rate within the
tu mor cal cu lated.  Fi nally, the min i mum dose rate in 
the tu mor (oc cur ring at the cen ter of the tu mor vol -
ume) was used to de  ter  mine the time re  quired to
reach a dose of 50 Gy-Eq (T50).  This en sures that all 
por  tions of the tu  mor re  ceive at least the  av er age
pre scribed  dose.  The  de ter mined  ir ra di a tion  time
was then used to cal cu late the max i mum dose to the
healthy tis  sue, in  clud  ing the skin (AT Dose at T50). 
The re sults are shown in fig. 3.  It must be noted that 
these cal  cu  la  tions as  sume that no bo  ron is pres  ent
within the healthy tis  sue, which is not a valid as  -
sump tion  when  us ing  pre vi ously  de vel oped  bo ron
de liv ery agents, such as BPA or BSH.  How ever, ex -
per  i  ments with OPDs in  di  cate that a large con  cen  -
tra  tion of the mol  e  cules re  main in the nu  cleus up to
and past 24 hours af  ter the up  take [7].  This should
pro  vide am  ple time for ex  cess car  rier mol  e  cules to
exit the blood stream al most en tirely.  Fur ther ex per -
i men ta tion  is  re quired  to  ver ify  this  as sump tion.
In ad  di  tion to the data dis  cussed above, the
dis tri bu tion of the dose within the tu mor is of in ter -
est, too. The data plot  ted in fig. 3 rep  re  sents the
max i mum  dose  to  healthy  tis sue  cor re spond ing  to
the time re  quired to ob  tain a min  i  mum dose of 50
Gy-Eq in the tu mor vol ume.  How ever, as it is de sir -
able to de  liver an equal dose to all parts of the tu  -
mor, the de vi a tion from the mean dose as a func tion
of its po si tion in the tu mor must be ex am ined.  This
data is presented in fig. 4.
DIS CUS SION  AND  CON CLU SION
As stated pre vi ously, the ob jec tive of this study 
was  to  de ter mine  the  tu mor  bo ron  con cen tra tion
re  quired to de  liver a le  thal dose to a breast tu  mor
(com  pa  ra  ble to that nor  mally pre  scribed in tra  di  -
tional ra dio ther apy) us ing BNCT while keep ing the 
dose to the healthy tis  sue be  low the skin tol  er  ance
level.  While the re sults of this ex per i ment pre sented 
in fig. 3 in  di  cate that a bo  ron con  cen  tra  tion as low
as 10 mg of 10B per gram of tis sue in the tu mor could 
sat  isfy this ob  jec  tive, other fac  tors must be taken
into ac count, too. For in stance, though a con cen tra -
tion of only 10 mg/g may be suf  fi  cient, a con  cen  tra  -
tion of 100 mg/g re  duces the ir  ra  di  a  tion time by a
fac tor of ap prox i mately 9.0, which cor re sponds to a
fac tor of an ap prox i mately 5.0 re duc tion in the dose
to the healthy tis  sue.  The ob  vi  ous ad  van  tages to a
higher bo  ron con  cen  tra  tion are a re  duced dose to
the healthy tis  sue, as well as an im  prove  ment in the
com  fort of the pa  tient as a re  sult of shorter ir  ra  di  a  -
tion times.
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Fig  ure 3. Max  i  mum dose to skin at T50 as a func  tion
of tu  mor bo  ron con  cen  tra  tion.  The solid line in  di  -
cates the ir  ra  di  a  tion time re  quired to ob  tain a min  i  -
mum dose of 50 Gy-Eq in the tu  mor vol  ume (T50)
and the dashed line in  di  cates the skin tol  er  ance
thresh old of 18 Gy-Eq.  As so ci ated com pu ta tional er -
rors are less than 1% and are not discernable at this
scale
Fig  ure 4. Dose rate vari  a  tion within the tu  mor vol  -
ume as a func tion of tu mor bo ron con cen tra tion.  The 
dark solid line in  di  cates the mean dose rate, while the
dot  ted and dashed lines in  di  cate the max  i  mum and
min  i  mum dose rates, re  spec  tively. The light solid line
in di cates  the  max i mum  de vi a tion  from  the  mean
dose.  As so ci ated  com pu ta tional  er rors  are  less  than
1% and are not discernable at this scaleAd  di  tion  ally, as in  di  cated by the data pre  -
sented in fig. 4, the vari  a  tion of the dose rate across
the  tu mor  vol ume  var ies  sig nif i cantly  with  bo ron
con  cen  tra  tion and must be con  sid  ered when de  ter  -
min ing  the  op ti mum  bo ron  con cen tra tion.    As  the
goal of any ra di a tion treat ment is to de liver an equal
dose to all por  tions of a tar  get vol  ume, ex  treme bo  -
ron con cen tra tions (low or high) may not be ad van -
ta  geous, as these points are rel  a  tive max  ima in the
deviation from the mean dose rate.
From both figs. 3 and 4, it ap pears that the op -
ti mum  tu mor  bo ron  con cen tra tion  for  the  treat -
ment of breast can  cer via BNCT is be  tween 50 and
60 mg of 10B per gram of tu  mor tis  sue.  This range
pro  vides a min  i  mum de  vi  a  tion from the mean dose
rate through  out the tu  mor vol  ume and re  quires a
work able  ir ra di a tion  pe riod  of  ap prox i mately  two
hours.  How ever, it must be re  it  er  ated that these re  -
sults are based upon the fol low ing as sump tions: (1)
that the tu  mor den  sity is 10% greater than that of
the sur  round  ing tis  sue, (2) that the RBE and CBE
val  ues for the Trastuzumab-OPD com  pound in a
breast tu mor are sim i lar to those of BPA and BSH in 
brain tu  mors and mel  a  noma, and (3) that the con  -
cen  tra  tion of bo  ron in healthy tis  sue is neg  li  gi  ble. 
The re  sults of this study are subject to experimental
verification of these assumptions.
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MONTE  KARLO  ANALIZA  BORONSKE  TERAPIJE  RAKA  DOJKE
Veliki broj `ena obolelih od raka dojke u SAD svake godine podle`e propisanom
efektivnom protokolu le~ewa koji nije ni malo jednostavan i lak. Ovaj rad fokusiran je na
analizu efikasnosti boronske neutronske terapije kao alternativnog pristupa le~ewu raka dojke
koji pokazuje proliferaciju HER-2 proteina. Koriste}i HER-2 specifi~na monoklonalna
antitela vezana za oligomerske molekule bogate boronskim jediwewima mogu}e je deponovati
zahtevanu koli~inu 10B u tumoru dojke {to bi omogu}ilo selektivno uni{tewe }elija tumora po
ozra~ivawu termalnim neutronima. Ovaj rad prikazuje detaqan model boronske terapije u
primeni raka dojke na bazi Monte Karlo programa MCNP5. Rezultati prora~una su analizirani u
pore|ewu sa konvencijalnom terapijom X-zra~ewem u pogledu poqa zra~ewa i deponovane doze
zra~ewa u tumoru i zdravom tkivu. Analize pokazuju da bi optimalna koncentracija 10B u tumoru
bila izme|u 50 i 60 mg po gramu tkiva tumora posmatraju}i vreme ozra~ivawa pacijenta, prostornu
raspodelu doze kao i vrednost doze koju primi ko`a u toku tretmana. Odre|ene pretpostavke
kori{}ene u ovom radu predmet su eksperimenata planiranih da se obave u SAD i Japanu.
Kqu~ne re~i:  boronska neutronska terapija, rak dojke, MCNP, OPD